Jylamvo®
Methotrexate oral solution
Methotrexate oral solution
For use in rheumatological, dermatological and oncological diseases
European Union Centralised Licence and Great Britain Licence
FDA approved
Marketing authorisation in UAE and Saudi Arabia
Key partners
There are opportunities available to commercialise Jylamvo in some territories.
To partner with us contact: bd@therakind.com
-
To ensure the medicine is used correctly and to avoid medication errors, Educational Materials are provided to all healthcare professionals who may potentially prescribe or dispense Jylamvo in Europe and GB. The Educational Package has been reviewed and approved by the relevant national regulatory authority for distribution in that particular market.
The educational package comprises the following documents:
Guide for healthcare professionals – prescribing physician and dispensing pharmacist.
The Summary of Product Characteristics (SmPC).
The Package Leaflet (PL).
Patient Card.
By clicking on these links, you confirm that you are a healthcare professional.
For information specific to GB, click here.
If you are not a healthcare professional, click here to return to the home page.
-
For Medical Information enquiries regarding Jylamvo or should you wish to report a Product Complaint or Adverse Event, please use the following contact details:
GB
Telephone: +44 (0)330 1359 437
Fax: +44 (0)190 8533 370
Email: medinfo.uk@esteve.com
-
For all sales enquiries for GB please contact Intrapharm:
Tel: +44 (0)1628 771 800
Fax: +44 (0)1628 771 524
Email: sales.uk@esteve.com